BioXcel Therapeutics

BTAI

Market cap $50.7M

Overview Fund Activity

3.17 USD

+0.06

1.93%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

3.17

0.00

0%

1 day

1.93%

5 days

-19.34%

1 month

-42.15%

3 months

87.57%

6 months

39.04%

Year to date

-49.44%

1 year

-69.04%

5 years

-99.59%

10 years

-98.2%

About: BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Employees: 37

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

275% more call options, than puts

Call options by funds: $15K | Put options by funds: $4K

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

54% more capital invested

Capital invested by funds: $770K [Q1] → $1.19M (+$419K) [Q2]

13% more funds holding

Funds holding: 30 [Q1] → 34 (+4) [Q2]

1.15% less ownership

Funds ownership: 11.52% [Q1] → 10.37% (-1.15%) [Q2]

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$4

26% upside

Avg. target

$27

741% upside

High target

$66

1,982% upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

HC Wainwright & Co. Raghuram Selvaraju	$10	Buy Reiterated	15 Sep 2025
Mizuho Graig Suvannavejh	$4	Neutral Maintained	12 Sep 2025
LUCID CAPITAL MARKETS Elemer Piros	$66	Buy Reiterated	15 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 11 articles about BTAI published over the past 30 days

BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript)

BioXcel Therapeutics, Inc. (NASDAQ:BTAI ) Discuses on SERENITY At-Home Pivotal Phase 3 Safety Trial Results Conference September 10, 2025 02:00 PM ET Company Participants Vimal Mehta - Founder, CEO, President, & Director Leslie Citrome - Clinical Professor of Psychiatry and Behavioral Sciences, New York Medical College Conference Call Participants Sumant Kulkarni - Canaccord Genuity Corp., Research Division Presentation Operator Greetings, and welcome to the BioXcel Therapeutics. [Operator Instructions] Please note that this call is being recorded.

BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript)

BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients

BioXcel Therapeutics, Inc. BTAI on Wednesday released topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated that BXCL501 had continued effects and consistent benefit with repeat dosing.

BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia

BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (p

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

NEW HAVEN, Conn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D.

BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment

BioXcel Therapeutics Inc. BTAI announced that its SERENITY At-Home Phase 3 trial of BXCL501—its sublingual dexmedetomidine film for acute agitation in bipolar disorder or schizophrenia—met its primary endpoint.

BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

BXCL501 achieved SERENITY At-Home's primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

BioXcel's agitation drug meets main goal in at-home study

BioXcel Therapeutics said on Wednesday its experimental agitation drug met the main goal of a late-stage study testing it in patients with bipolar disorder or schizophrenia for at-home use.

BioXcel's agitation drug meets main goal in at-home study

BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

BXCL501 achieved SERENITY At-Home's primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia

BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025

NEW HAVEN, Conn., Aug. 26, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it will host an investor call and live webcast at 8 a.m.

BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025

BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Data from more than 2,600 agitation episodes collected Topline data readout is on track for August NEW HAVEN, Conn., Aug. 19, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced completion of the database lock for its SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia.

BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

See News Rankings

Charts implemented using Lightweight Charts™